Tests finerenone in people with IgA nephropathy, a kidney disease
Tests finerenone added to standard care in adults with IgA nephropathy.
Plain-language title generated from the registry record
Registry title: Finerenone in Patients With IgA-nephropathy: Prospective Interventional Trial
Key facts
- Where
- Moscow, RussiaSee the site
Where in Russia
- Botkin HospitalMoscow, RussiaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Botkin Hospital
- Trial code
- NCT07056595
- Record updated
- 9 July 2025
- Original description
: IgA-nephropathy is the most common glomerulonephritis with the unfavorable prognosis in patients with persistent albuminuria. Finerenone is a new nonsteroidal mineralocorticoid receptor antagonist that has demonstrated efficacy in reducing albuminuria in patients with CKD and type 2 diabetes in two major trials, FIGARO-DKD and FIDELIO. This finding supported the approval of finerenone by the U.S. Food and Drug Administration (FDA) for the treatment of chronic kidney disease (CKD). A subgroup analysis in the pooled FIDELITY trial demonstrated that in patients with CKD stages 1-4 and type 2 diabetes (T2D), the cardio- and nephroprotective effects of finerenone were independent of concomitant therapy with SGLT-2 inhibitors or GLP-1 receptor agonists. Thus, the role of finerenone in slowing CKD progression in T2D can be considered well-established. Given its albuminuria-reducing effects, finerenone is being investigated in multiple trials, including studies on non-diabetic kidney disease and IgA nephropathy, though no published results are available yet. In this trial finerenone will be used as a nephroprotective agent above standard treatment in terms of assessing adverse events and potential efficacy.Read full original descriptionShow less
Finerenone in Patients With IgA-nephropathy: Prospective Interventional Trial
: IgA-nephropathy is the most common glomerulonephritis with the unfavorable prognosis in patients with persistent albuminuria. Finerenone is a new nonsteroidal mineralocorticoid receptor antagonist that has demonstrated efficacy in reducing albuminuria in patients with CKD and type 2 diabetes in two major trials, FIGARO-DKD and FIDELIO. This finding supported the approval of finerenone by the U.S. Food and Drug Administration (FDA) for the treatment of chronic kidney disease (CKD). A subgroup analysis in the pooled FIDELITY trial demonstrated that in patients with CKD stages 1-4 and type 2 diabetes (T2D), the cardio- and nephroprotective effects of finerenone were independent of concomitant therapy with SGLT-2 inhibitors or GLP-1 receptor agonists. Thus, the role of finerenone in slowing CKD progression in T2D can be considered well-established. Given its albuminuria-reducing effects, finerenone is being investigated in multiple trials, including studies on non-diabetic kidney disease and IgA nephropathy, though no published results are available yet. In this trial finerenone will be used as a nephroprotective agent above standard treatment in terms of assessing adverse events and potential efficacy.
Inclusion: Adults (> 18 years) with the primary IgAN diagnosed by kidney biopsy; Treatment with stable doses of iRAS or/and iSGLT2 inhibitors for at least 3 months prior inclusion into the trial; Blood pressure < 140/90 mm Hg; 24-hour urinary albumin excretion > 300 mg.
Exclusion: Kidney transplantation in medical history; Acute myocardial infarction and/or stroke less then 3 months before including in trial; Chronic hepatic disease, including hepatitis, malignant tumor, active malignancy; Heart failure with ejection fraction <40%; Presence ANCA in serum; eGFR < 20 ml/min; Ongoing immunosuppressive treatment; Pregnancy and breastfeeding; Uncontrolled blood pressure.